Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

May’s top stories: Gilead’s Phase II viral drug study, CytoDyn’s HIV drug

Gilead Sciences reported that its investigational oral RSV fusion inhibitor 'GS-5806' met primary and secondary endpoints in Phase IIa challenge trial, while CytoDyn dosed the first patients in its Phase IIb clinical trial, a treatment substitution protocol for patients with human immunodeficiency virus, with its lead product candidate, PRO140. Drugdevelopment-technology.com wraps-up the key headlines from May 2014.

Go Top